Novartis India DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023


0.77×	0.69×	0.90×
1.46×	1.96×	1.95×
25.0%	18.7%	15.6%
0.38×	0.35×	0.39×
1.21×	1.24×	1.27×
13.0%	11.1%	13.5%
13.2%	11.2%	13.3%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

NOVARTIND₹1,812.80

Novartis India Limited

· Pharma & Health

₹ CrorePeersBPLPHARMA JENBURPH KPL MAKERSL PARNAXLAB SGRL SHUKRAPHAR SUNLOC

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.90	0.69	0.77
Interest Burden (Pretax/EBIT) ×	1.95	1.96	1.46
EBIT Margin %	15.58	18.70	25.05
Asset Turnover ×	0.39	0.35	0.38
Financial Leverage (Assets/Equity) ×	1.27	1.24	1.21
ROE (5-step product, year-end total equity) %	13.49	11.05	12.99
ROE (owners' profit / average owners' equity) %	13.33	11.21	13.19

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY25 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.